3,092
Views
24
CrossRef citations to date
0
Altmetric
Review

Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection

, &

References

  • Winston A, Underwood J. Emerging concepts on the use of antiretroviral therapy in older adults living with HIV infection. Curr Opin Infect Dis. 2015;28(1):17–22.10.1097/QCO.0000000000000117
  • Ando M, Yanagisawa N. Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patients. World J Nephrol. 2015;4(3):388–395.10.5527/wjn.v4.i3.388
  • Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008;22(3):395–402.10.1097/QAD.0b013e3282f423dd
  • Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002;16(9):1257–1263.10.1097/00002030-200206140-00008
  • Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS. 2004;18(7):1074–1076.10.1097/00002030-200404300-00019
  • Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191–201.10.1001/jama.292.2.191
  • Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867–875.10.1097/QAD.0b013e328351f68f
  • Hemkens LG, Ewald H, Santini-Oliveira M, et al. Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis. HIV Clin Trials. 2015;16(5):178–189.10.1179/1945577115Y.0000000004
  • Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta‐analysis: renal safety of tenofovir disoproxil fumarate in HIV‐infected patients. Clin Infect Dis. 2010;51(5):496–505.10.1086/652979
  • Winston J, Chonchol M, Gallant J, et al. Discontinuation of Tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies. HIV Clin Trials. 2014;15(6):231–245.10.1310/hct1506-231
  • Fafin C, Pugliese P, Durant J, et al. Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1.73 m. Nephron – Clin Pract. 2012;120(4):c205–c214.
  • Laprise C, Baril J-G, Dufresne S, Trottier H. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis. 2013;56(4):567–575.10.1093/cid/cis937
  • Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825–831.10.1097/QAD.0b013e32835192ae
  • Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest. 2009;89(5):513–519.10.1038/labinvest.2009.14
  • Jafari A, Khalili H, Dashti-Khavidaki S. Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol. 2014;70(9):1029–1040.10.1007/s00228-014-1712-z
  • Gilead Sciences. Prescribing information for VIREAD®. 2015. Available at http://www.gilead.com/~/media/files/pdfs/medicines/hiv/viread/viread_pi.pdf?la=en. Accessed November 4, 2015.
  • Bristol Myers Squibb GS. Prescribing information for ATRIPLA®. 2015. Available at http://packageinserts.bms.com/pi/pi_atripla.pdf. Accessed November 4, 2015.
  • Gilead Sciences. Prescribing information for COMPLERA®. 2015. https://gilead.com/~/media/files/pdfs/medicines/hiv/complera/complera_pi.pdf. Accessed November 4, 2015.
  • Gilead Sciences. Prescribing information for STRIBILD®. 2015. Available at http://www.gilead.com/~/media/files/pdfs/medicines/hiv/stribild/stribild_pi.pdf?la=en. Accessed November 4, 2015.
  • Hoetelmans R, Van Heeswijk R, Kestens D. Pharmacokinetic interaction between the novel nonnucleoside reverse transcriptase inhibitor (NNRTI) TMC278 and tenofovir disoproxil fumarate (TDF) in healthy volunteers. 3rd IAS Conference on HIV Pathogenesis, Treatment and Prevention, Brazil, July 2005, abstract WePe3.3C15.
  • European Commission Health and Food Safety. Tybost product characteristics. Available at http://ec.europa.eu/health/documents/community-register/2015/20150210131020/anx_131020_en.pdf. Accessed May 2, 2016.
  • Droste JA, Kearney BP, Hekster YA, Burger DM. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;41(1):37–43.10.1097/01.qai.0000191997.70034.80
  • Gilead Sciences. Prescribing information for emtricitabine/tenofovir disoproxil fumarate tablets (Truvada®). Available at http://www.gilead.com/~/media/files/pdfs/medicines/hiv/truvada/truvada_pi.pdf. Last updated December, 2013. Accessed November, 2015.
  • Jotwani V, Scherzer R, Estrella M, et al. Associations of tenofovir disoproxil fumarate with urine biomarkers of kidney damage. Conference on Retroviruses and Opportunistic Infections (CROI): February 22–25, 2016. Boston, MA, USA2016.
  • Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4):449–455.10.1097/QAI.0b013e3182965d45
  • Mills A, Crofoot G Jr, McDonald C, Shalit P, Flamm JA, Gathe J Jr, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2015;69(4):439–445.10.1097/QAI.0000000000000618
  • Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–2615.10.1016/S0140-6736(15)60616-X
  • Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67(1):52–58.10.1097/QAI.0000000000000225
  • Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43–52.10.1016/S1473-3099(15)00348-5
  • Rijnders B, Stephan C, Lazzarin A, et al. Switching from boosted atazanavir plus emtricitabine /tenofovir disoproxil fumarate to a tenofovir alafenamide-based single-tablet regimen: week-48 data in virologically suppressed adults [abstract 577]. 15th European AIDS Conference, October 21–24, 2015 Bacelona, Spain2015.
  • Shamblaw D, Lunzen JV, Orkin C, et al. Switching from atripla (ATR) to a tenofovir alafenamide (TAF)-based single tablet regimen: week 48 data in virologically suppressed adults. ICAAC, Septemeber 17–21, 2015. San Diego, CA, USA2015.
  • Thompson M, Morales-Ramirez J, McDonald C, et al. Switching from a TDF to a TAF-based single tablet regimen: week 48 data in HIV-1 infected virologically suppressed adults [abstract 725]. IDSA / ID Week, October 7–11, 2015 San Diego, CA, USA2015.
  • Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Version 2.0. Last updated November, 2014. Available at http://rsc.tech-res.com/Document/safetyandpharmacovigilance/DAIDS_AE_Grading_Table_v2_NOV2014.pdf. Accessed March 16, 2016.
  • German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61(1):32–40.10.1097/QAI.0b013e3182645648
  • Del Palacio M, Romero S, Casado JL. Proximal tubular renal dysfunction or damage in HIV-infected patients. AIDS Rev. 2012;14(3):179–187.
  • OCEBM Levels of Evidence Working Group. The Oxford levels of evidence 1: Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=1025. Accessed February 15, 2016.
  • Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annal Int Med. 2009;151(4):264–269, W264.10.7326/0003-4819-151-4-200908180-00135
  • Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–384.10.1136/jech.52.6.377
  • Jadad AR, Carroll D, Moore A, McQuay H. Developing a database of published reports of randomised clinical trials in pain research. Pain. 1996;66(2):239–246.10.1016/0304-3959(96)03033-3
  • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408–412.10.1001/jama.1995.03520290060030
  • Rockstroh JK, Lennox JL, DeJesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53(8):807–816.10.1093/cid/cir510
  • Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238–246.10.1016/S0140-6736(11)60936-7
  • Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir Plus abacavir/lamivudine for the treatment of HIV-1 Infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015;70(5):515–519.10.1097/QAI.0000000000000790
  • Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63(1):77–85.10.1097/QAI.0b013e31828ace69
  • Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–1818.10.1056/NEJMoa1215541
  • Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154(7):445–456.10.7326/0003-4819-154-7-201104050-00316
  • Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835):2439–2448.10.1016/S0140-6736(12)60917-9
  • Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63(1):96–100.10.1097/QAI.0b013e318289545c
  • Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65(3):e118–e120.10.1097/QAI.0000000000000057
  • Gutierrez F, Fulladosa X, Barril G, Domingo P. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Rev. 2014;16(4):199–212.
  • Campbell TB, Smeaton LM, Kumarasamy N, et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med. 2012;9(8):e1001290.10.1371/journal.pmed.1001290
  • Touzard Romo F, Smeaton LM, Campbell TB, et al. Renal and Metabolic toxicities following initiation of HIV-1 Treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). HIV Clin Trials. 2014;15(6):246–260.10.1310/hct1506-246
  • DeJesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009;51(2):163–174.10.1097/QAI.0b013e3181a572cf
  • Ouattara E, Danel C, Moh R, Gabillard D, Peytavin G, Konan R, et al. Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts. J Int AIDS Soc. 2013;16:18059.
  • Cohen C, Wohl D, Arribas JR, et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS. 2014;28(7):989–997.10.1097/QAD.0000000000000169
  • Pujari S, Dravid A, Gupte N, Joshix K, Bele V. Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India. J Int AIDS Soc. 2008;10(8):196.10.1186/1758-2652-10-8-196
  • Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47(1):74–78.10.1097/QAI.0b013e31815acab8
  • Moyle GJ, Stellbrink HJ, Compston J, et al. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther. 2013;18(7):905–913.10.3851/IMP2667
  • Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015;373(8):705–713.10.1056/NEJMoa1501315
  • German P, Pang PS, Fang L, Chung D, Mathias A. Drug-drug interaction profile of the fixed-dose combination tablet ledipasvir/sofosbuvir. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, November 7–11, 2014. [ Abstract.]
  • Nelson MR, Elion RA, Cohen CJ, et al. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE studies. HIV Clin Trials. 2013;14(3):81–91.10.1310/hct1403-81
  • Overton ET, Chan ES, Brown TT, et al. Vitamin D and Calcium attenuate bone loss with antiretroviral therapy initiation: A randomized trial. Ann Intern Med. 2015;162(12):815–824.10.7326/M14-1409
  • McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791–1801.10.1093/infdis/jir188
  • Gupta SK, Mi D, Moe SM, Dubé MP, Liu Z. Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial. J Acquir Immune Defic Syndr. 2013;64(3):279–283.10.1097/QAI.0b013e3182a97c39
  • Lazzarin A, Johnson M, Ribera E, Weitner L, Chen SS, Warren DR. 5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF). J Int AIDS Soc. 2010;13(Suppl 4):P6.10.1186/1758-2652-13-S4-P6
  • Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21(10):1273–1281.10.1097/QAD.0b013e3280b07b33
  • Symphony Health Solutions. PatientSource APLD and Source® PHAST prescription monthly, equivalized counts, January 2007–December 2015. http://symphonyhealth.com/product/pharmaceutical-audit-suite-phast/.
  • U.S. Food and Drug Administration. Approved and Tentatively Approved Antiretrovirals in Association with the President’s Emergency Plan. http://www.fda.gov/InternationalPrograms/PEPFAR/ucm119231.htm. Accessed July 11 2016.
  • World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach - Second edition (2016). http://www.who.int/hiv/pub/arv/arv-2016/en/. Accessed October 18 2016.
  • Bagnis CI, Stellbrink HJ. Protease inhibitors and renal function in patients with HIV infection: a systematic review. Infect Dis Therapy. 2015;4:15–50.
  • Albini L, Cesana BM, Motta D, et al. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-Infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr. 2012;59(1):18–24.10.1097/QAI.0b013e31823a6124
  • Dazo C, Fahey P, Puls R, et al. Small but significant and non-progressive decline in GFR observed in therapy-naïve HIV+ subjects commencing r/ATV, compared to either EFV or ZDV/ABC with TDF/FTC after 48 weeks: a randomized controlled study. Paper #841 presented at the 18th Conference on Retroviruses and Opportunistic Infections (CROI): February 22–March 2, 2011. Boston, MA.
  • Lepist EI, Phan TK, Roy A, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother. 2012;56(10):5409–5413.10.1128/AAC.01089-12
  • Ofotokun I, Titanji K, Vunnava A, et al. A single dose zoledronic acid prevents antiretroviral-induced bone loss. Presented at the Conference on Retroviruses and Opportunistic Infections, Boston, February 22–25, 2016.
  • Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796–806.10.1016/S0140-6736(09)60918-1
  • Lennox JL, DeJesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010;55(1):39–48.10.1097/QAI.0b013e3181da1287
  • Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204(8):1191–1201.10.1093/infdis/jir505
  • Puls R, Amin J, Losso M, et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet. 2014;383(9927):1474–1482.
  • Carey D, Puls R, Amin J, et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015;15(7):793–802.
  • Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251–260.10.1056/NEJMoa051871
  • Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes – a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43(5):535–540.
  • Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2009;51(5):562–568.10.1097/QAI.0b013e3181ae2eb9
  • Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55(1):49–57.10.1097/QAI.0b013e3181dd911e
  • DeJesus E, Ruane P, McDonald C, et al. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials. 2008;9(2):103–114.10.1310/hct0902-103
  • Erlandson KM, Kitch D, Tierney C, et al. Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS. 2013;27(13):2069–2079.10.1097/QAD.0b013e328361d25d
  • Wohl DA, Orkin C, Doroana M, et al. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO). Antivir Ther. 2014;19(2):191–200.10.3851/IMP2721
  • Tebas P, Kumar P, Hicks C, et al. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. AIDS. 2015;29(18):2459–2464.10.1097/QAD.0000000000000863
  • Havers FP, Detrick B, Cardoso SW, et al. Change in vitamin D levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings. PLoS ONE. 2014;9(4):e95164.10.1371/journal.pone.0095164
  • Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir‐lamivudine versus tenofovir‐emtricitabine in HIV‐infected adults: 48‐week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963–972.10.1086/652982
  • Grant PM, Kitch D, McComsey GA, Tierney C, Ha B, Brown TT. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults. HIV Clin Trials. 2015;16(2):66–71.10.1179/1528433614Z.0000000010